Therapeutic strategies targeting the endothelial glycocalyx.
Journal
Current opinion in clinical nutrition and metabolic care
ISSN: 1473-6519
Titre abrégé: Curr Opin Clin Nutr Metab Care
Pays: England
ID NLM: 9804399
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
pmc-release:
01
11
2024
medline:
10
10
2023
pubmed:
9
8
2023
entrez:
9
8
2023
Statut:
ppublish
Résumé
This review will highlight recent studies that have examined the endothelial glycocalyx in a variety of health conditions, as well as potential glycocalyx-targeted therapies. A degraded glycocalyx is present in individuals that consume high sodium diet or have kidney disease, diabetes, preeclampsia, coronavirus disease 2019 (COVID-19), or sepsis. Specifically, these conditions are accompanied by elevated glycocalyx components in the blood, such as syndecan-1, syndecans-4, heparin sulfate, and enhanced heparinase activity. Impaired glycocalyx barrier function is accompanied by decreased nitric oxide bioavailability, increased leukocyte adhesion to endothelial cells, and vascular permeability. Glycocalyx degradation appears to play a key role in the progression of cardiovascular complications. However, studies that have used glycocalyx-targeted therapies to treat these conditions are scarce. Various therapeutics can restore the glycocalyx in kidney disease, diabetes, COVID-19, and sepsis. Exposing endothelial cells to glycocalyx components, such as heparin sulfate and hyaluronan protects the glycocalyx. We conclude that the glycocalyx is degraded in a variety of health conditions, although it remains to be determined whether glycocalyx degradation plays a causal role in disease progression and severity, and whether glycocalyx-targeted therapies improve patient health outcomes. Future studies are warranted to investigate therapeutic strategies that target the endothelial glycocalyx.
Identifiants
pubmed: 37555800
doi: 10.1097/MCO.0000000000000973
pii: 00075197-990000000-00103
pmc: PMC10592259
mid: NIHMS1921135
doi:
Substances chimiques
Heparin
9005-49-6
Sulfates
0
Types de publication
Review
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
543-550Subventions
Organisme : NCCIH NIH HHS
ID : R00 AT010017
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG050238
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG060395
Pays : United States
Organisme : NIA NIH HHS
ID : R44 AG053131
Pays : United States
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Metabolism. 2023 Feb;139:155377
pubmed: 36521550
JCI Insight. 2022 Aug 8;7(15):
pubmed: 35763350
Int J Mol Sci. 2022 Nov 18;23(22):
pubmed: 36430770
Am J Physiol Heart Circ Physiol. 2018 Sep 1;315(3):H531-H539
pubmed: 29750566
J Clin Med. 2022 Jun 09;11(12):
pubmed: 35743370
Biomedicines. 2022 Nov 02;10(11):
pubmed: 36359309
Arterioscler Thromb Vasc Biol. 2023 Mar;43(3):427-442
pubmed: 36700429
Naunyn Schmiedebergs Arch Pharmacol. 2021 May;394(5):1003-1007
pubmed: 33443616
Clin Hemorheol Microcirc. 2020;75(3):257-265
pubmed: 31683466
Crit Care. 2020 Dec 14;24(1):696
pubmed: 33317589
Eur J Heart Fail. 2022 Apr;24(4):727-729
pubmed: 35138689
Curr Opin Pharmacol. 2019 Apr;45:66-71
pubmed: 31112922
Clin Hemorheol Microcirc. 2022;81(3):205-219
pubmed: 35342082
Placenta. 2022 Aug;126:64-69
pubmed: 35779415
Am J Physiol Heart Circ Physiol. 2022 Feb 1;322(2):H156-H166
pubmed: 34890278
Biochim Biophys Acta Mol Basis Dis. 2022 May 1;1868(5):166368
pubmed: 35202791
J Clin Med. 2022 Dec 15;11(24):
pubmed: 36556051
Vascul Pharmacol. 2022 Jun;144:106975
pubmed: 35248780
Int J Mol Sci. 2022 Sep 13;23(18):
pubmed: 36142571
Pflugers Arch. 2007 Jun;454(3):345-59
pubmed: 17256154
Diabetologia. 2022 May;65(5):879-894
pubmed: 35211778
J Clin Med. 2023 Jan 10;12(2):
pubmed: 36675479
Am J Physiol Heart Circ Physiol. 2022 Feb 1;322(2):H328-H335
pubmed: 34995168
ERJ Open Res. 2022 May 03;8(2):
pubmed: 35509442
BMB Rep. 2023 May;56(5):314-319
pubmed: 37013347
Sci Rep. 2022 Jul 25;12(1):12681
pubmed: 35879337
Nutrients. 2022 Oct 21;14(20):
pubmed: 36297099
J Appl Physiol (1985). 2022 May 1;132(5):1297-1309
pubmed: 35439042
J Rheumatol. 2017 Nov;44(11):1603-1611
pubmed: 28916547
Circ Res. 2018 Sep 14;123(7):825-848
pubmed: 30355078
Front Physiol. 2022 Oct 13;13:1022770
pubmed: 36311221
Angiogenesis. 2023 Feb;26(1):53-61
pubmed: 35951203
Am J Physiol Regul Integr Comp Physiol. 2021 Apr 1;320(4):R508-R518
pubmed: 33501896
JCI Insight. 2023 Mar 8;8(5):
pubmed: 36749631
Front Immunol. 2022 Jun 10;13:916512
pubmed: 35757776
Am J Pathol. 2023 Feb;193(2):138-147
pubmed: 36414084
Front Immunol. 2022 Sep 02;13:984298
pubmed: 36119052
Pflugers Arch. 2022 Oct;474(10):1069-1076
pubmed: 35867189
Front Immunol. 2023 Jan 26;14:1129766
pubmed: 36776845
Int J Mol Sci. 2022 Dec 08;23(24):
pubmed: 36555160
PLoS One. 2022 Mar 2;17(3):e0264650
pubmed: 35235593
Pflugers Arch. 2011 Oct;462(4):519-28
pubmed: 21796337
Sci Rep. 2022 May 24;12(1):8733
pubmed: 35610344
Viruses. 2022 Feb 22;14(3):
pubmed: 35336857
Am J Physiol Heart Circ Physiol. 2023 Apr 1;324(4):H473-H483
pubmed: 36735405
Geroscience. 2023 Feb 14;:
pubmed: 36787090
Angiogenesis. 2021 Feb;24(1):145-157
pubmed: 33058027
Cardiovasc Drugs Ther. 2023 Apr;37(2):307-313
pubmed: 34792686
Annu Rev Biomed Eng. 2007;9:121-67
pubmed: 17373886
Cytokine. 2022 Jan;149:155723
pubmed: 34662822
Am J Physiol Heart Circ Physiol. 2021 Jan 1;320(1):H404-H410
pubmed: 33306450
Glycobiology. 2022 Jul 13;32(8):720-734
pubmed: 35552402
Kidney Int Rep. 2021 Dec 16;7(4):797-809
pubmed: 35497798
Geroscience. 2022 Jun;44(3):1657-1675
pubmed: 35426600
Exp Physiol. 2022 Jul;107(7):694-707
pubmed: 33904234
Front Nutr. 2023 Jan 06;9:1090023
pubmed: 36687716
Pharmacol Rep. 2006;58 Suppl:75-80
pubmed: 17332675
J Matern Fetal Neonatal Med. 2022 Dec;35(25):7466-7470
pubmed: 34238103
Front Cardiovasc Med. 2021 Nov 02;8:727888
pubmed: 34796208